Emyria has released its Annual Report, highlighting key achievements over the past 12 months, including: the commencement of human trials for Ultra-Pure CBD capsule candidate EMD-RX5, expanding our MDMA Analogue Partnership with UWA, and our partnership with Tenmile to accelerate drug development programs.

We’re immensely proud of our achievements in the past year, and we look forward to sharing further milestones.

You can read the Annual Report here